Baird Medical Investment vs Sonoma Pharmaceuticals
BDMD and SNOA side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BDMD and SNOA compare
Sonoma Pharmaceuticals grew revenue faster over the last twelve months (38.7% versus −39.2% for Baird Medical Investment).
Sonoma Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −7.6% compared with −121% at Baird Medical Investment.
Sonoma Pharmaceuticals scores higher on the StockData Score (11 against 2 for Baird Medical Investment), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BDMD | SNOA |
|---|---|---|
| Size and price | ||
| Market cap | – | $5.9M |
| Share price | $0.104 | $1.24 |
| Change, 1 year | −91.7% | −66.0% |
| Change, 5 years | – | −98.9% |
| Beta (5Y) | −0.04 | 1.95 |
| Employees | 146 | 250 |
| StockData Score | ||
| Total score | 2 | 11 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 0 | 3 (better) |
| Performance score | 0 | 2 (better) |
| Health score | 2 | 3 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 0.3× |
| P/B | – | 0.9× |
| FCF yield | – | −47.0% |
| Fair value | – | $5.17 |
| Margin of safety | – | 76.0% |
| Growth | ||
| Revenue growth (TTM) | −39.2% | 38.7% (better) |
| Revenue growth, 5Y average | – | 0.95% |
| Net income growth (TTM) | −319% | – |
| EPS growth (TTM) | −272% | – |
| Profitability | ||
| Gross margin | 83.8% (better) | 39.2% |
| Operating margin | −114% | −3.3% (better) |
| Net margin | −121% | −7.6% (better) |
| FCF margin | −6.2% (better) | −11.9% |
| Return on equity | −77.5% | −34.5% (better) |
| Return on invested capital | −48.2% | −42.9% (better) |
| Financial health | ||
| Debt / equity | 0.22 | 0.01 (better) |
| Interest coverage | −72.3× | – |
| Current ratio | 1.29 | 3.48 (better) |
| Altman Z-score | – | −14.15 |
| Piotroski F-score | 1 | 3 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | −72.0% |
| Shareholder yield | – | −72.0% |
| Ownership | ||
| Held by institutions | – | 2.3% |
| Held by insiders | 62.0% | 11.1% |
| Short interest, % of float | – | 1.6% |
Go deeper
- BDMD stock overview
- BDMD income statement
- BDMD valuation and score
- SNOA stock overview
- SNOA income statement
- SNOA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.